For more than 300 years since its foundation in 1717, working for people’s health. Diseases still unconquered. Patients' wishes still unfulfilled. ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.

Discover ONO PHARMA USA, a pharmaceutical company dedicated to bringing patients innovative medicines in oncology, immunology, neurology, and specialty.

ONO PHARMA USA was established in 1998 as the United States subsidiary of ONO PHARMACEUTICAL CO., LTD., a pharmaceutical company founded in Osaka, Japan in 1717. …

Basic informationUpholding the corporate philosophy "Dedicated to the Fight against Disease and Pain," we remain fully committed to creating original and innovative new drugs.

2025.03.12 ライセンス 米国Ionis Pharmaceuticals社と真性多血症治療薬「Sapablursen」に関するライセンス契約を締結 2025.03.10 研究開発 ブリストル マイヤーズ スクイブ、欧州委員会より切除不能または進行肝細胞がん成人患者のファーストライン治療としてオプジーボとヤーボイの併用療法の承認を取得 ...

Apr 30, 2024 · Through this Acquisition, ONO is pleased to welcome Deciphera as a partner with commercial capabilities in the United States and Europe and excellent research and development capabilities in the field of cancer. This combination will further enhance ONO’s pipeline and accelerate its globalization.

In September 2010, Ono entered into a license agreement with Onyx Pharmaceuticals, Inc. (currently a subsidiary of Amgen) to exclusively develop and commercialize two proteasome inhibitors, carfilzomib (ONO-7057) and oprozomib (ONO-7058) for the treatment of any types of cancers in Japan.

Commitment to Conservation of the Global Environment Information Disclosure Based on the TCFD Recommendation Information Disclosure Based on the TNFD Recommendations

Company Profile Management Business Locations ONO Story R＆D Manufacturing Activities for Disseminating Academic Information

Oct 24, 2024 · Discover the wide range of therapies ONO Pharma USA is investigating across oncology, neurology, immunology, and specialty.